BENLYSTA® (Belimumab) is an immunosuppressive drug used to treat active Systemic Lupus Erythematosus.
BENLYSTA® is manufactured by GlaxoSmithKline (GSK).
Administration and Dosage:
Administration of BENLYSTA® follows an induction regimen of 3 intravenous infusions at 2-week intervals followed by a maintenance infusion, once every 4 weeks.
Common Side Effects:
The more common side effects of BENLYSTA® include nausea, diarrhea, fever, stuffy or runny nose and sore throat, persistent cough, trouble sleeping, leg or arm pain, depression, headache, pain, redness, itching, swelling at the site of injection (when given subcutaneously), progressive multifocal leukoencephalopathy (PML), and cancer.
Ready to Schedule an Appointment?
Please CLICK HERE to get started.
BENLYSTA® is indicated to treat:
- Systemic Lupus Erythematosus